Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01571960 · ClinicalTrials.gov registry record · Phase 1

Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults

A Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 1
Development phase
48
Enrollment target
4
Study locations

NCT01571960: Completed Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT01571960 is a Phase 1 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 48 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (89% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01571960, a Phase 1 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 1
Development phase
48 participants
Enrollment target
4
Study locations

Study Summary

This study will test the safety and immune responses of a prime-boost regimen of two HIV vaccines- a DNA vaccine followed by a modified vaccinia Ankara (MVA) vaccine- in healthy, HIV-uninfected, vaccinia-naive adults.

Primary Outcome

Signs and symptoms include pain, tenderness, erythema, induration, and maximum severity of pain and/or tenderness.

Conditions Studied

Interventions

  • BIOLOGICAL GEO-D03 DNA vaccine
  • BIOLOGICAL MVA/HIV62B (MVA62B) vaccine
  • BIOLOGICAL Placebo for GEO-D03 DNA
  • BIOLOGICAL Placebo for MVA62B:

Study Locations (4)

Alabama

  • Alabama CRS - Birmingham

California

  • Bridge HIV CRS - San Francisco

Massachusetts

  • Brigham and Women's Hospital Vaccine CRS (BWH VCRS) - Boston

New York

  • University of Rochester Vaccines to Prevent HIV Infection CRS - Rochester

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2012-04
Est. Completion 2016-01
Phase Phase 1

What the finished NCT01571960 record still lists

NCT01571960 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (89% lower).

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 4 interventions - of which GEO-D03 DNA vaccine is the first listed.

NCT01571960 reports a single indexed study location in Alabama, California, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01571960 about?

NCT01571960 is a clinical study titled "Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults". This study will test the safety and immune responses of a prime-boost regimen of two HIV vaccines- a DNA vaccine followed by a modified vaccinia Ankara (MVA) vaccine- in healthy, HIV-uninfected, vaccinia-naive adults.

What is the current status of trial NCT01571960?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2012-04. Estimated completion is 2016-01.

What conditions does trial NCT01571960 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT01571960?

The interventions under investigation include: GEO-D03 DNA vaccine (BIOLOGICAL), MVA/HIV62B (MVA62B) vaccine (BIOLOGICAL), Placebo for GEO-D03 DNA (BIOLOGICAL), Placebo for MVA62B: (BIOLOGICAL).

Who is sponsoring clinical trial NCT01571960?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01571960 being conducted?

This trial has 4 study locations across Alabama, California, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01571960's enrollment target sits among peer trials

48 367th of 542 higher than 168 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01765777 · 48 participants · NA

    Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain

  • NCT03073343 · 48 participants · NA

    A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

  • NCT03431064 · 48 participants

    Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients

  • NCT03514602 · 48 participants · NA

    Maternal Smoking Cessation and Pediatric Obesity Prevention

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01571960, the US trial registry maintained by the National Library of Medicine. NCT01571960 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.